IRX 4204
Alternative Names: AGN-194204; ALRT-4204; IRX-4204; NRX-194204; NRX-4204; VTP-194204Latest Information Update: 24 Sep 2024
Price :
$50 *
At a glance
- Originator Allergan
- Developer Icahn School of Medicine at Mount Sinai; Io Therapeutics
- Class Antihyperglycaemics; Antineoplastics; Antiparkinsonians; Small molecules; Tetrahydronaphthalenes
- Mechanism of Action Nuclear receptor subfamily 4 group A member 2 agonists; Retinoid X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer; Prostate cancer
- Phase I HER2 positive breast cancer; Parkinson's disease
- Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Arthritis; Neurodegenerative disorders
- Discontinued Multiple sclerosis
Most Recent Events
- 19 Sep 2024 Pharmacodynamics data from a preclinical trial in Neurodegenerative disorders released by Io Therapeutics
- 18 Sep 2024 Io Therapeutics plans a phase II trial in Parkinson’s disease in Q1 of 2025
- 16 Jul 2024 Preclinical trials in Amyotrophic lateral sclerosis in USA (PO), prior to July 2024